Please use this identifier to cite or link to this item:
|Title:||Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia|
Marque, Cristiane R.
Maia-de-Oliveira, Joao P.
Ferrari, Thiago B.
Santos, Antonio C.
Machado-de-Sousa, Joao P.
Bressan, Rodrigo A. [UNIFESP]
Crippa, Jose A.
Guimaraes, Francisco S.
Zuardi, Antonio W.
Baker, Glen B.
Dursun, Serdar M.
Hallak, Jaime E. C.
Universidade de São Paulo (USP)
Natl Sci & Technol Inst Translat Med INCT TM
Univ Fed Rio Grande do Norte
Universidade Federal de São Paulo (UNIFESP)
|Citation:||Schizophrenia Research. Amsterdam: Elsevier B.V., v. 161, n. 2-3, p. 439-445, 2015.|
|Abstract:||Increasing evidence suggests that the tetracycline antibiotic minocycline has neuroprotective effects and is a potential treatment for schizophrenia. However, the mechanisms of action of minocycline in the CNS remain elusive. the aim of this study was to investigate the effects of minocycline on brain morphology and cerebral perfusion in patients with recent-onset schizophrenia after 12 months of a randomized double-blind, placebo-controlled clinical trial of minocycline add-on treatment. This study included 24 outpatients with recent-onset schizophrenia randomized for 12 months of adjuvant treatment with minocycline (200 mg/d) or placebo. MRI (1.5 T) and [Tc-99m]-ECD SPECT brain scans were performed at the end of the 12-month of trial. Between-condition comparisons of SPECT and MRI brain images were performed using statistical parametric mapping and analyzed by voxel-based morphometry (VBM). Minocycline adjuvant treatment significantly reduced positive and negative symptoms when compared with placebo. the VBM analysis of MRI scans showed that the patients in the placebo group had significant lower gray matter volumes in the midposterior cingulate cortex and in the precentral gyrus in comparison with the patients in the minocycline group. in addition, a decreased ECD uptake in the minocycline condition was observed in fronto-temporal areas. These results suggest that minocycline may protect against gray matter loss and modulate fronto-temporal areas involved in the pathophysiology of schizophrenia. Furthermore, minocycline add-on treatment may be a potential treatment in the early stages of schizophrenia and may ameliorate clinical deterioration and brain alterations observed in this period. (C) 2014 Elsevier B.V. All rights reserved.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.